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Inflammatory Responses 
Reprogram TReGs Through 
Impairment of Neuropilin-1
Tim Hung-Po Chen1, Manoj Arra1, Gabriel Mbalaviele4, Gaurav Swarnkar1 &  
Yousef Abu-Amer  1,2,3
Chronic inflammatory insults compromise immune cell responses and ultimately contribute to 
pathologic outcomes. Clinically, it has been suggested that bone debris and implant particles, such as 
polymethylmethacrylate (PMMA), which are persistently released following implant surgery evoke 
heightened immune, inflammatory, and osteolytic responses that contribute to implant failure. 
However, the precise mechanism underlying this pathologic response remains vague. TReGs, the 
chief immune-suppressive cells, express the transcription factor Foxp3 and are potent inhibitors of 
osteoclasts. Using an intra-tibial injection model, we show that PMMA particles abrogate the osteoclast 
suppressive function of TReGs. Mechanistically, PMMA particles induce TReG instability evident by reduced 
expression of Foxp3. Importantly, intra-tibial injection of PMMA initiates an acute innate immune and 
inflammatory response, yet the negative impact on TReGs by PMMA remains persistent. We further show 
that PMMA enhance TH17 response at the expense of other T effector cells (TEFF), particularly TH1. At 
the molecular level, gene expression analysis showed that PMMA particles negatively regulate Nrp-1/
Foxo3a axis to induce TReG instability, to dampen TReG activity and to promote phenotypic switch of TReGs 
to TH17 cells. Taken together, inflammatory cues and danger signals, such as bone and implant particles 
exacerbate inflammatory osteolysis in part through reprogramming TReGs.
Inflammatory osteolysis is a major complication of orthopedic joint implants1. Debris released from these 
implants trigger immune and inflammatory responses that promote recruitment of macrophages and osteoclasts 
to the injury site2. This cell- and cytokine-based pathologic response accelerates bone erosion around the implant 
leading to loosening and ultimately failure of implants, which poses high morbidity and mortality risks. Despite 
extensive efforts, the details of the biologic response to implant debris remain enigmatic and the complete rep-
ertoire by which orthopedic particles modulate cell lineages to enhance inflammation and exacerbate osteolysis 
remains poorly understood.
The cellular response to inflammatory triggers, including PMMA and bone particles, entails recruitment and 
activation of myeloid and immune cells such as macrophages, dendritic cells, granulocytes and lymphocytes. The 
ensuing inflammatory response is consistent with release of wear particles from implants and intensifies with 
increased particle burden akin to chronic response3–5. These particles are largely associated with inflammatory 
macrophages and osteoclasts at the implant-bone interface. However, the presence of multitude of other immune 
cell types, especially lymphocytes was also noted6–10. T lymphocytes mediate the adaptive phase of the immune 
response and are typically activated by antigen presenting cells such as dendritic cells. The most frequent subsets 
of these cells in inflammatory loci include T regulatory (TREG) and T helper (TH) cells. TREG cells express the tran-
scription factor Foxp3 and elicit inhibitory activity. On the other hand, TH cells can differentiate based on their 
response to specific sets of factors in their microenvironment into TH1, TH17, or TH2 subtypes. Whereas TH1 and 
TH17 respectively secrete TNFα, IFNγ and IL-17A among many other pro-inflammatory cytokines, TH2 cells 
secrete primarily anti-inflammatory mediators including IL-4 and IL-1011.
The specific contribution of lymphocytes to wear debris-induced inflammatory osteolysis remains controver-
sial. In this regard, circumstantial findings point to potential direct lymphocyte involvement as well as indirect 
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action through secretion of pro-inflammatory and pro-osteoclastogenic factors such as RANKL, IL-17A, M-CSF 
or anti-osteoclastogenic factors such as IFNγ and IL-49,12–15. Notably, we have shown recently that mice harboring 
loss-of-function mutant foxp3 in T cells display severe osteopenia16. This finding led us to speculate that reduced 
immunosuppression is conceivably one of the major reprogramming of immune cells elicited by PMMA particles 
during the progression of inflammatory osteolysis. Hence, the goal of this study is to decipher the pathologic 
mechanisms by which implant debris modulate lymphocytes to exacerbate inflammatory osteolysis. To this end, 
we show that PMMA particles, likely through a stress mechanism, modulate T cell activation by down-regulating 
Foxp3 function, resulting with T cell phenotypic switch from TREG into pathogenic TH cells with enhanced 
NF-κB activity. Mechanistically, we provide evidence that particles down regulate expression of Nrp-1 leading to 
reprogramming of TREGS. This change not only renders TREGS incapable of inhibiting osteoclasts, but they secrete 
pro-osteoclastogenic and pro-inflammatory factors that expand the myeloid-progenitor population and enhance 
osteoclastogenesis.
Results
PMMA particles induce NF-κB activity and alter bone marrow cellularity toward reduced 
immunosuppression. We have shown previously that PMMA particles robustly activate NF-κB in myeloid 
cells leading to pro-inflammatory and pro-osteolytic conditions17,18. We have also shown recently that activity of 
NF-κB is exacerbated under conditions of TREG cell inactivity wherein the transcription factor foxp3 is mutated16. 
To further examine the cellular response to PMMA, we established a new experimental mouse model whereby 
PMMA particles or vehicle were injected directly into the proximal tibia using a 27G syringe. At different time 
points post injection, in vivo NF-κB reporter activity was measured. In addition, myeloid cells and lymphocytes 
from bone marrow and spleen were FACS sorted and quantified. Our data indicate that NF-κB luciferase activ-
ity in the whole bone marrow of PMMA-injected RelA-luc reporter mice was significantly (4 folds) elevated 
compared with baseline activity in control PBS-injected mice (Fig. 1a). We then used FACS analysis to examine 
the cellular response locally at the site of PMMA injection, namely the tibia and at adjacent femurs. The data 
depicted in Fig. 1 indicate that as early as two days post injection, PMMA particles induced two-fold increase in 
all myeloid progenitor populations examined, including lineage−c-Sca-1+c-kit+ hematopoietic stem cells (LSK 
HSCs) lineage−c-kit+CD34+Fcγ− common myeloid progenitors (CMPs) and lineage−c-kit+CD34+F4/80+ gran-
ulocyte-macrophage progenitors (GMPs) (Fig. 1b) while significantly reducing Foxp3+ TREG cells in tibia bone 
marrow (Fig. 1c) and marginally affecting cellularity in adjacent femurs (data not shown). We also examined the 
compartment of more committed and mature myeloid populations in the bone marrow and found frequencies 
of CD11b+Gr1+ granulocytic cells were elevated in PMMA injected tibias, while the frequency of CD11b+Gr1− 
monocytic cells was unaffected (Fig. 1d). Furthermore, these cellular changes summoned a moderately yet signifi-
cantly elevated osteoclastogenic potential of whole bone marrow cells, indicating PMMA also increased osteoclast 
progenitors and/or their osteoclastogenic potential at the injection site (Fig. 1e,f).
PMMA particles modulate extra-medullary hematopoiesis in the spleen. To evaluate plausible 
systemic response to PMMA injection in the tibia, we examined NF-κB activity and hematopoiesis in the spleen. 
Similar to what was observed in the tibia (i.e. local response), NF-κB luciferase activity was also significantly ele-
vated in either whole spleen cells or splenic CD4+ T cells (Fig. 2a,b). The number of spleen CD4+CD25+Foxp3+ 
TREG cells two days post-injection was also significantly reduced (Fig. 2c) whereas frequency of CD11b+Gr1+ 
cells that include but not limited to neutrophils and myeloid derived suppressive cells (MDSCs) was signifi-
cantly increased (Fig. 2d). CD4+CD25+Foxp3+ TREG in the periphery including the blood and lymph nodes were 
also significantly decreased (Fig. S1). These findings suggest that PMMA particles elicit an acute inflammatory 
response that extends from pro-inflammatory marrow macrophages to systemic pro-inflammatory neutrophils, 
granulocytes and immunosuppressive MDSC cells. This further suggests that PMMA-induced changes in the 
marrow elicit systemic responses, likely cytokine-mediated signaling, to modulate immune responses in the 
spleen, lymph nodes and peripheral blood. Thus, this inflammatory cascade may initiate a vicious cycle that mag-
nifies the severity of PMMA-induced osteolytic disease.
The increase of myeloid progenitors in response to PMMA is transient, while the reduction 
of regulatory T cells is prolonged. To further dissect the in vivo response of PMMA, we followed the 
changes of myeloid progenitor and regulatory T cell population in the bone marrow over time from 2 to 7 days 
after intra-tibial injection of PMMA. To monitor the systemic response, we extended our analyses to cellular 
changes in the spleen, lymph nodes and blood. We found that the significant increase of myeloid progenitor 
populations including LSKs, CMPs and GMPs rapidly diminished as early as 4 days post injection (Fig. 3a–c). 
In contrast, PMMA-induced decrease of TREG frequency remained persistent in the bone marrow and in the 
spleen of intra-tibially injected animals even after 7 days (Fig. 3d,e). Concomitantly, peripheral blood granulo-
cytic neutrophils were also increased early after injection (2 days) and gradually declined back to the level similar 
to PBS injected animals (Fig. 3f). Finally, RelA-luciferase reporter activity, a measure of NF-κB activity, was 
also normalized systemically 7 days after injection, as no significant difference was found between PMMA- and 
PBS-injected mice in both the spleen and lymph nodes (Fig. S2a,b). However, immunostaining for Luciferase in 
bone sections from PMMA-injected tibias and luciferase activity of the bone marrow cells derived from PMMA 
injected tibias remained significantly increased (Fig. 3g,h). Consistent with the observed normalized systemic 
response, NF-κB activity also declined in femurs one-week post PMMA injection to adjacent tibias (Fig. 3h, 
marked with #). More importantly, when we performed functional assessment of osteoclast precursor numbers 
by ex vivo osteoclastogenesis assay, whole bone marrow cells from PMMA injected tibia and from adjacent femurs 
retained significantly higher osteoclastogenic potential than those from the PBS-injected controls (Fig. 3i). Since 
the numbers of myeloid progenitors were normal at this stage post PMMA injection, PMMA was most likely to 
3Scientific RepoRts |         (2019) 9:10429  | https://doi.org/10.1038/s41598-019-46934-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
potentiate and sensitize osteoclast progenitors versus increase their numbers at early stage. These results suggest 
that PMMA elicits a prolonged dampening of immunosuppression by TREGS, which may lead to unrestrained 
inflammatory response already triggered by significant increase in frequency of innate immune cells, e.g. mac-
rophages. Although tibial injection resulted in temporal systemic inflammatory response, elevated NF-κB activity 
persisted at the injection site.
Figure 1. PMMA particles induce NF-κB activity and alter bone marrow cellularity toward reduced 
immunosuppression. (a) PMMA particles induced local NF-κB activation in immune cells. Total cells were 
isolated from the bone marrow of RelA-Luciferase reporter mice post PMMA intra-tibial injection. After 
removal of red blood cells, mononucleated cells from bone marrow of separated femurs and tibias were lysed 
to assess luciferase activity, which was normalized by protein concentration determined by standard BCA 
assay. (b) Increase of myeloid progenitor cells in the bone marrow of mice 2 days post intra-tibial injection of 
PMMA particles revealed by flow cytometric analysis. 1 × 107 mononucleated bone marrow cells were stained 
with FACS antibodies to assess myeloid progenitor populations including LSK HSCs, CMPs and GMPs. (c) 
Decreased frequency of bone marrow CD4+CD25+Foxp3+ TREG by intra-tibial PMMA injection. (d) Alterations 
of bone marrow myeloid lineages. Monocytic myeloid cells are marked as CD11b+Gr-1− and granulocytic 
cells as CD11b+Gr-1+. (e,f) Assessment of osteoclastogenic potential of whole bone marrow cells (WBM) 
by ex vivo osteoclastogenesis assay (OCgenesis) 2 days after intra-tibial injection of PMMA. 50,000, 100,000 
or 200,000 total bone marrow cells were cultured in 96-well plates supplemented with CMG and RANKL to 
achieve optimal cell density for osteoclast formation. After 4 days of culture, cells were fixed before subjected 
TRAP staining to visualize osteoclasts. Cells with expanded cytoplasm and more than 3 nuclei were counted 
as matured osteoclasts. (e) Representative images and quantification of the number of multi-nucleated (MNC) 
osteoclasts per well counted from triplicates of three independent experiments. All columns in the graphs were 
represented as mean ± SD. *p < 0.05; **p < 0.005 or as indicated by Student T-test.
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PMMA particles enhance expression of markers of pathogenic TH effector cells. The increased 
local and systemic inflammatory burden along with significant reduction in TREG frequency in response to 
PMMA exposure prompted us to further interrogate changes in T cell populations that may contribute to this 
pathology. In this regard, it has been shown previously that under inflammatory conditions, TREG cells may lose 
their immunosuppressive phenotype and assume a TH effector pathogenic phenotype19–23. This phenotypic switch 
depends on suppression or inactivation of Foxp3.
Supporting a potential pathogenic switch of TREG cells into TH effector cells, we found that 2 days post 
intra-tibial injection of PMMA, bone marrow derived CD4+ T effector cells possessed significantly higher per-
centage of Foxp3lo RORγT+ cells (Fig. 3j). Interestingly, utilizing Foxp3 GFP reporter mice in which expression 
of GFP and Foxp3 are coupled, not only did we observe reduced number of CD4+CD25+TREG in situ (bone mar-
row), extramedullary (spleen) and in periphery (blood and lymph node) upon intra-tibial injection of PMMA 
(Fig. S3a–d), it was also accompanied by increased mRNA expression of TH17 markers IL-17A, RORγt, RUNX1 
and a large number of other inflammatory and osteoclastogenic factors including TNFα, RANKL and M-CSF 
(Fig. 4a–f). Similar results were also obtained from spleen TEFF cells post PMMA injection (Fig. S4a–f) particu-
larly for RORγt/RUNX1/IL-17, but to a lesser extent for other effector/pro-inflammatory cytokines. These results 
show increased frequency of TEFF at the expense of TREG cells, suggesting potential T cell phenotype switching.
In vivo effect of PMMA on Treg can be recapitulated ex vivo. It is reasonable to postulate that the 
negative impact of PMMA on TREGS is mediated by secondary mechanisms as it mostly requires the engagement 
of T-cell receptor (TCR) signaling and antigen presentation by innate immune cells such as dendritic cells and 
macrophages24. However, mechano-transduction of T cells has been recently conceptualized and investigated25 
and therefore, PMMA may also target TREG (and TEFF) in a direct manner. To gain further insights into the effect 
Figure 2. PMMA particles induce NF-κB activity and modulate extra-medullary hematopoiesis in the 
spleen. (a) PMMA particles induced NF-κB activation in immune cells. Total cells were isolated from the 
spleen from post PMMA intratibially injected animals. After removal of red blood cells, mononucleated 
cells were lysed to assess luciferase activity, which was normalized by protein concentration determined by 
standard BCA assay. (b) CD4+ T helper were further fractionated before measurements of luciferase activity 
normalized either by total protein input or cell number (not shown). (c) Decreased frequency of bone marrow 
CD4+CD25+Foxp3+TREG in the spleen of PMMA injected animals. (d) Alterations of myeloid lineages. All 
columns in the graphs were represented as mean ± SD. *p < 0.05 by Student T-test.
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of PMMA on T cells including both TREGs and TEFF (direct vs. indirect mechanism), we conducted ex vivo cultures 
of whole bone marrow (WBM), whole spleen (WSpl) and whole lymph node (WLN) cells. Freshly isolated cells 
were cultured overnight in the presence of PMMA. These heterogeneous cultures were then stimulated with pan 
stimulator PMA/ionomycin for 5 hrs. Non-PMMA treated and -PMA/ionomycin stimulated cultured served as 
controls. Interestingly, in cultures from all 3 sources, percentage of CD3+CD4+CD25+ TREG was reduced by over-
night treatment of PMMA, regardless of PMA/ionomycin stimulation (Fig. 4g–i). Reduction of TREGS was signif-
icantly greater in the WBM than in the WSpl and WLN cultures. Furthermore, percentage of IL-17A expressing 
cells in the CD3+CD4+CD25− TEFF population was significantly increased in WBM culture by PMMA treatment 
(Fig. 4j). WSpl derived TEFF cells also exhibited a trend of increased frequency of IL-17A+ population in the 
presence of PMMA (Fig. 4k), while the percentage of IL-17A+ T effector cells in the WLN culture was unaltered 
(Fig. 4l). Because WBMs and WSpls constitute significant proportion of myeloid cells (of the innate immune sys-
tem; >40% for WBM and >5% for WSpl) compared to WLNs that is considered negligible proportion of myeloid 
cells (<1%), these data strongly suggest that secondary mechanisms (i.e. myeloid/T-cell interaction) most likely 
play a larger role in the effect of PMMA on TREG and TEFF cells.
Figure 3. Increase of myeloid progenitors in response to PMMA is transient, while reduction of regulatory T 
cells is prolonged. (a) Frequency of bone marrow myeloid progenitor LSK, (b) CMP and (c) GMP 2, 4 and 7 days 
after intra-tibial injection of PMMA. (d) Frequency of TREG in the bone marrow (BM) and (e) in the spleen (Spl) 
over time. (f) Frequency of granulocytes in the mononuclear peripheral blood cells (PB/MNCs) over time. (g) 
IHC for Luciferase and FoxP3 from Control and PMMA-treated conditions. Arrows point to reactive staining 
(h) Quantification of normalized NF-κB reporter activity in WBM cells isolated from femur and tibia 7 days after 
intra-tibial (i.t.) injection of PMMA. # denotes femur adjacent to injected tibia. (i) Assessment of osteoclastogenic 
potential of WBM cells by ex vivo osteoclastogenesis assay (OCgenesis) 7 days after intra-tibial injection of 
PMMA. (j) % of CD4+CD25+ FoxP3loRORγt+ T cells in the bone marrow (BM) of mice treated as described in 
H-I. All columns in the graphs were represented as mean ± SD. *p < 0.05; **p < 0.005 by Student T-test.
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PMMA particles impair the osteoclast suppressive function of TREGS. To explore the poten-
tial mechanisms by which PMMA affects TREG cell phenotype, we conducted co-culture and transwell studies 
(Fig. 5). CD4+CD25+ TREG cells were isolated by MACS and either co-cultured with BMMs or cultured in tran-
swells with BMMs at the bottom of the plate. RANKL was added to BMMs to promote osteoclastogenesis fol-
lowed by stimulating some wells with PMMA particles. Half of TREGS were treated with PMMA particles and 
the other half were left untreated. Additionally, 2,000U of human recombinant IL-2 was also supplemented to 
Figure 4. Increase of TH17 immunity, upregulation of inflammatory factors produced by effector T cells and 
recapitulation of the in vivo PMMA effect on TREG by ex vivo cultures. (a–c) CD4+CD25− effector T cells (TEFF) 
were enriched by magnetic bead sorting (MACS) and lysed in Trizol reagent for RNA isolation. After cDNA 
synthesis through reverse transcription (RT), quantitative polymerase chain reaction (qPCR) was performed 
to assess mRNA expression of TH17 markers including IL-17A, RORγt and RUNX1. (d–f) Expression of 
proinflammatory/pro-osteoclastogenic cytokines including M-CSF, RANKL and TNFα were also measured 
by qRT-PCR. Expression of tubulin was used as loading control. ΔCq values were calculated by Cq value of 
each given gene divided by that of tubulin. Plots were generated by values that were normalized with mock PBS 
injected control group. (g–i) Frequencies of CD4+CD25+Foxp3+TREG in whole bone marrow (WBM), whole 
spleen (WSpl) and while lymph node (WLN) cells were assessed by flow cytometry after overnight incubation 
with 0.4% PMMA. (j–l) Frequencies CD4+CD25+CD44+IL-17A+ TEFF were also analyzed. All columns in the 
graphs were represented as mean ± SD. *p < 0.05; **p < 0.005 by Student T-test.
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support immune suppressive function of all CD4+CD25+ TREG cells. As expected, adding TREG cells to BMMs in 
co-culture drastically inhibited RANKL stimulated osteoclastogenesis (Figs 5a and S5; compare corresponding 
panels I, II and III in both figures). Interestingly, whereas TREGs in co-culture with BMMs sufficiently interfered 
with PMMA-exacerbated osteoclastogenesis (Figs 5a and S5; corresponding panel IV), pre-treatment of TREGS 
with PMMA particles prior to co-culture with BMMs impaired TREGS anti-osteoclastogeneic function (Figs 5a 
and S5, panels V and VI compared with panel III). This impaired TREG function was detected in both co-culture 
and transwell (Fig. 5a, panels VIII and IX) conditions. Notably, when PMMA was added to the BMM compart-
ment, TREGS were only partially able to inhibit the exacerbated osteoclastogenesis (Fig. 5a; panels IV and VIII). 
Interestingly, when we monitored mRNA expression of pro-inflammatory cytokines to assess reprogramming of 
TREGS, we observed a 12-fold increase of IL-17A expression in the TREG co-cultured with BMM stimulated with 
PMMA (Fig. 5b). On the other hand, we did not see significant changes of IL-17A expression or other inflamma-
tory cytokines in the TREG cultured in transwells with BMMs undergoing PMMA exacerbated osteoclastogenesis 
Figure 5. Inhibition of osteoclastogenesis by TREG in the presence of PMMA is Nrp1-mediated event. (a) 
MACS-purified TREG were either co-cultured with bone marrow derived macrophages (BMMs) or placed in the 
upper chambers of transwell cultures with BMMs in the lower chambers. RANKL and M-CSF were added at 
the beginning of cell culture and again after 2 days to promote osteoclastogenesis. PMMA particles were added 
to BMMs or TREGS as indicated. After 4 days, TREG cells were separated from cultures before TRAP staining was 
performed to visualize osteoclast formation. Results from BMM-TREG co-cultures and BMM-TREG transwell 
cultures are marked accordingly. (b–e) Isolated TREG from co-cultures and transwell upper chambers were lysed 
in Trizol reagent for RNA isolation. cDNAs were subsequently generated for qPCR analysis. (f) Immunostaining 
for Nrp1 in bone sections from control and PMMA-treated mice. (g) Osteoclast differentiation (+/−PMMA 
treated TREGS) as described in panel A in the absence or presence of intact TREGS or TREGS transduced with 
scrambled (scr) shRNA or Nrp-1 shRNA. (h) Osteoclast differentiation (as described above) in the absence or 
presence of vehicle or PMMA-treated TREGS. Some conditions include overexpression of retroviral Nrp-1 in 
TREGS (as indicated). (i) Representative images of osteoclast cultures quantified in panel h. All columns in the 
graphs were represented as mean ± SD. *p < 0.05; **p < 0.005; ***p < 0.001 by Student T-test.
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(Fig. 5c and data not shown). These observations suggest that TREG cells, while partially affected by direct contact 
with PMMA, they require direct cell- cell contact with BMMs to achieve potent anti-osteoclastogenic potential. 
The data also suggest that TREGS secreted factors appear to play a role in their anti-osteoclastogenic function, albeit 
to a lesser degree than direct cell-cell contact. Most importantly, the data suggest that PMMA particles, through 
their action on TREGS, alter the phenotype of these cells from suppressors to IL-17A expressing T cells, suggesting 
a phenotypic switch.
PMMA particles impede the TReG anti-osteoclastogenic function by reprogramming TReGs 
through inhibition of neuropilin-1. To further delineate the mechanism affected by direct impact on 
T cells, qRT-PCR analysis was performed to survey mRNA expressions of genes that are important for the 
immune suppressive function of TREG and/or stability of TREG. To this end, we observed slight upregulation of 
Icos and GITR, and no change for Eos and CTLA4 in the presence of PMMA (Fig. S6a–f). We also did not see 
any changes of CTLA4 expression in TREG cells among all culture conditions (Fig. S5g,h). However, among the 
markers tested, only neuropillin-1 (Nrp-1) was downregulated in the TREG cells under all culture conditions with 
PMMA (Fig. 5d–f). Most notably, loss of Nrp-1 expression (resulting from exposure to PMMA) or by shRNA 
(Figs 5d and S5) rendered TREGS incapable of inhibiting osteoclastogenesis (Figs 5g and S5). Most interestingly, 
retroviral expression of Nrp-1 in TREGS halted the negative effect of PMMA on these cells and strongly stabilized 
and augmented their anti-osteoclastogenic function (Fig. 5h,i). These observations suggest that stable expression 
of Nrp-1 and its downstream signaling, stabilizes TREGS and supports its immunosuppressive function. The data 
further suggest that danger signals, such as PMMA particles, cause diminution of Nrp-1, which triggers TREG to 
undergo phenotypic switch to TEFF (i.e. exTREG), and exacerbate osteoclastogenesis.
Discussion
In this study we show that intra-tibial injection of PMMA particles increases the frequency of premature myeloid 
progenitors LSKs, granulocytic CD11b+Gr1+ cells and reduce frequency of CD4+CD25+ TREG cells. We further 
show that NF-κB reporter activity is significantly increased in vivo concurrent with inhibition of Foxp3 and ele-
vated expression of TH17 transcription factors Runx1 and RORγt, leading to over production of inflammatory 
and osteoclastogenic factors such as TNFα, RANKL, M-CSF and IL-17A. These observations suggest that PMMA 
particles specifically attenuate TREG suppressive activity by inhibiting Foxp3 and switching the T cell phenotype 
from immunosuppressive to pathogenic.
In previous work, we have shown that PMMA particles exacerbate osteoclastogenesis in whole bone marrow 
cultures. Thus, it is reasonable to suggest that PMMA particles elicit an inflammatory microenvironment that 
alters hematopoiesis, highlighted by increased frequency of primitive progenitors such as LSKs. Concurrently 
PMMA particles induce conditions favorable for suppressing TREGS and promoting pathogenic TH17 cell through 
down regulation of Foxp3. Taken together, the sum of these changes lead to higher inflammatory and osteoclas-
togenic burdens. Indeed, Foxp3 is indispensable for TREG suppressive function. Mechanistically, Bettelli et al.26 
found that Foxp3 associates with NFAT and NF-κB proteins and hinders their transcriptional activity. In fact, we 
and others have shown that myeloid and T cells derived from scurfy mice, which harbor inactive mutant Foxp3, 
exhibit high levels of NFAT and NF-κB activity, supporting the notion that Foxp3-expressing TREG cells suppress 
effector T helper cells16. In this study, using foxp3-GFP reporter mice, we provide direct evidence supporting 
TREG phenotype switch in response to the PMMA inflammatory signals. Specifically, we observe reduced number 
of CD4+CD25+ TREG in situ (bone marrow), extramedullary (spleen) and in periphery (blood and lymph node) 
upon intra-tibial injection of PMMA, concurrent with increased mRNA expression of TH17 markers RORγt, and 
IL-17A. Consistent with the paradigm that Foxp3 provides a transcriptional switch in T cell differentiation, it has 
been shown that T helper cells, specifically TH17, may originate from Foxp3+ TREG cells20. According to this study, 
inflammatory conditions render Foxp3 unstable leading to trans-differentiation of TREG cells that just lost Foxp3 
expression, so-called exFoxp3, into TH17 pathogenic cells. It was further shown that this cell phenotype conversion 
was mediated by IL-6 and was associated with increased expression of IL-23R, RANKL, and Chemokine Receptor 
6 (CCR6). More importantly, these exFoxp3 TH17 pathogenic cells were primarily located at sites on inflammation 
in arthritic joints. Our data suggest that PMMA particles destabilize TREGS through diminution of Foxp3.
Previous studies have shown that inflammatory conditions, such as synovial joint inflammation, destabilized 
foxp3 in TREGS leading to impaired cell function27, increased TH17 effector cells and unleashed the activity of the 
proinflammatory transcription factors NFAT and NF-κB. Multiple mechanisms are involved in the control of 
TREG stability28. These include PI3 kinase/Foxo29, Nrp-1/semaphorin-4a/Foxo3a30, GITR signaling31 and USP21 
deubiquitinase32. Moreover, several other genes also participate in the balance between TREG and TH17 cells such 
as Foxo3a/TSC133,34, TCR and cytokine signaling integrated by Itk35, Tpl236, Eos37, TNF/TNFR238, Notch39, coop-
erated signaling between TCR and CD28/CTLA440. Interestingly, when we survey expression of these genes to 
determine the potential targets of PMMA-mediated TREG instability, we found that Nrp-1 expression was signif-
icantly downregulated. Thus, the mechanism underlying TREG reprogramming (e.g. reduced foxp3 expression) 
appears to involve down regulation of Nrp-1 via undefined stress or danger-like apparatus. As a result, NF-κB 
activity is elevated leading to induction of pro-inflammatory and osteoclastogenic factors including TNF, IL-17A, 
RANKL and M-CSF. This ultimately leads to increased osteoclastogenic burden through increased myeloid pro-
genitor numbers and increased CD11b+Gr1+ myeloid cells. Furthermore, since Nrp-1 is a cell-surface protein/
receptor, it is reasonable to speculate that PMMA particles interact with Nrp-1 and elicit mechano-transduction 
signals. In fact, our data indicate that primed spleen CD4+CD25+ TREG (stimulation with anti-CD3/CD28 beads 
for 72 hours) exhibited decreased Foxp3 protein expression in the presence of PMMA. Moreover, CD4+CD25− 
TEFF culture under the same conditions with much lower concentration of supplemented IL-2 (30U rather than 
2,000) possessed higher RORγt+ population. Perhaps the most compelling evidence supporting this phenomenon 
is our finding that restoring expression of Nrp-1 via viral transduction stabilized the suppressive phenotype of 
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TREGS and render these cells irresponsive to the inflammatory impact of PMMA particles. These data suggest that 
PMMA, beyond its conventional role in innate immunity (targeting macrophages; the precursors of osteoclasts), 
could directly impact the adaptive immunity with unknown mechanisms that require further investigation.
It is well documented that the CTLA4 is required for inhibition of osteoclastogenesis by TREG through direct 
cell- cell contact, at least in vitro. This TREG-osteoclast interaction is mediated by CTLA4 expressed by TREG 
and CD80/86 expressed by osteoclast. Not only CD80/86 osteoclast can escape inhibition by TREG, more con-
vincingly CD80/86 deficient mice are osteopenic and exhibit increased osteoclast differentiation ex vivo. That 
said, we did not see any change in mRNA expression of CTLA4 in TREG co-cultured with BMM undergoing 
PMMA-exacerbated osteoclastogenesis. Ultimately, functional tests will be required with crucial reagents such 
as CTLA4-Fc to rule out whether PMMA can affect CTLA4-mediated (or GITR, PD-1 etc.) osteoclastogenesis 
suppression by TREG. It is important to note that murine CD4+CD8+FoxP3+ TREGS inhibit osteoclastogenesis 
in a cell contact-dependent manner with minor contribution by circulating anti-inflammatory cytokines41. In 
contrast, human FoxP3+TREGS induce alternative activation and inhibit osteoclast differentiation from peripheral 
blood monocytes independent of cell contact, yet in a TGFβ and IL-4-dependnet manner42,43. Although varying 
experimental conditions may contribute to this discrepancy, it would be of interest to simultaneously determine 
Nrp1 expression and function in these two systems.
Our co-culture experiments show that while TREGS potently inhibit osteoclastogenesis, exposure of TREGS to 
PMMA particles impair their anti-osteoclastogeneic function. Moreover, under co-culture conditions, PMMA 
particles induce robust expression of proinflammatory cytokines by TREG cells, suggesting that macrophage-TREG 
contact is crucial for this response. This observation, which is highlighted by secretion of IL-17A and TNFα by 
exTREG cells, is reminiscent of TREG phenotype switching and assuming an effector function. On the other hand, 
marginal osteoclast inhibition by TREGS in transwell conditions, suggest that PMMA particles may marginally 
induce secretion of soluble factors by macrophages that adversely influence secretion of repressors factors by TREG 
cells. These observations are consistent with the established paradigm wherein TH17 serve as osteoclastogenic TH 
cell type linking T cell activation with bone resorption through the interleukin IL23-IL17 axis44. Further deline-
ation of the subsets of pathological effector T cells induced by orthopedic particles vs. rheumatoid diseases may 
have significant therapeutic implications.
In sum, our findings show that, in addition to its well documented direct effect on osteoclasts, PMMA parti-
cles also induce inflammatory osteolysis by modulating TREG cells. Specifically, we suggest that PMMA particles, 
by yet to be defined mechanism, down regulate Nrp-1 leading to reduced foxp3 and subsequent reprogramming 
TREGS into TH17 pathogenic cells. These cells express pro-inflammatory and osteoclastogenic factors that directly 
expand the osteoclast progenitor population and exacerbate osteoclastogenesis. Our findings identify the Nrp-1 
pathway as a potential therapeutic target to combat inflammatory osteolysis.
Materials and Methods
Study design and statistical analysis. Data is expressed as mean ± SD of at least three independent 
experiments. Typically, each experimental design includes triplicates of each condition. *p < 0.05; **p < 0.005 
using Student t-test. Our experimental design is based on reaching 0.05 significance and effect size of 25%. With 
desired difference of 80%, we calculated sample size as 6 mice per group. Experiments were conducted with male 
and female mice at equal proportions. There are no reported osteolytic differences between mouse sexes.
Mice. Approval for using animals was obtained from Washington University School of Medicine Institutional 
Animal Care and Use Committee in accordance with NIH guidelines prior to performing this study. Mice were 
housed at the Washington University School of Medicine barrier facility. NF-κB reporter (NGL) mice were pur-
chased from Jackson Laboratories to monitor in vivo NF-κB activity longitudinally during disease progression 
as well as ex vivo studies including cultures of macrophages/monocytes, proinflammatory T helper cells and 
co-cultures. Foxp3-GFP reporter mice were kindly provided by Dr. John DiPersio’s lab (Washington University) 
and were originally from Jackson Laboratories (Bar Harbor, ME USA). The Foxp3 reporter mice were used to 
perform hematological diagnosis by flow cytometry for TREG cells, myeloid populations and progenitors after 
manipulation.
Chemicals and reagents. PMMA particles (Polyscience) were sterilized before injection by washing with 
70% EtOH for three times followed by 3 times in PBS and finally resuspended in PBS (0.2 mg/ml for in vitro stud-
ies and 20 ul per injection of 5 mg/ml in vivo). All FACS antibodies, buffers and reagents were purchased from 
either BD Biosciences, eBioScience/Thermo Fisher or BioLegend.
Flow cytometry. To analyze myeloid progenitor in the bone marrow, freshly flushed WBM cells were 
sequentially stained with PE conjugated anti-CD34 and Brilliant Blue 421 conjugated anti-CD16/32 antibodies 
for 30 minutes on ice, and biotin conjugate lineage antibody cocktail (anti-CD2, -CD3ε -IL7R, -Ter119 and –
B220) and PerCP Cy5.5 anti-CD11b, PE Cy7 anti-CD115 (c-fms), Alexa 700 anti-Ly6G and APC H7 anti-CD117 
(c-kit) antibodies for additional 30 minutes. After washed with FACS buffer, antibody labeled cells were stained 
with Brilliant Blue 510 conjugated streptavidin for 20 minutes before analyzed on flow cytometer. To phenotype 
T cells, whole bone marrow (WBM) or whole spleen (WSpl) cells were stained with PE anti-CD4, PerCP Cy5.5 
anti-CD44, APC anti-CD62L, PE Cy7 anti-CD3ε, APC e780 anti-CD8a and Brilliant Blue 421 anti-CD25 for 
30 minutes on ice.
Intra-tibial injection mouse model to test acute/short-term cellular response to PMMA. Mice 
were anesthetized with 100 μl of ketamine/xylazine cocktail per 10 grams of body weight. Skin above the knee 
cap was wetted with 70% EtOH to sterilize and visualize the injection site. To allocate the growth plate of tibia, 
1 0Scientific RepoRts |         (2019) 9:10429  | https://doi.org/10.1038/s41598-019-46934-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
patellar ligament was used as a landmark. 27G needle was inserted above the patellar ligament until encountering 
resistance. Drill motion was applied to the needle until the growth plate was penetrated. 20 μl of PBS or PMMA 
solution (5 mg/ml) was released into the bone marrow cavity slowly to avoid back flash.
Cell Isolation and culture. Bone marrow macrophages/monocytes (BMMs). Bone marrow cells were har-
vested from femurs and tibias. After cell numbers were determined by hemacytometer counts, cells were cultured 
in DMEM supplemented with 10% FBS and 10% CMG that contained M-CSF.
CD4+CD25+TREG. CD4+CD25+ cells were isolated from mouse spleens by MACS according to manufac-
turer’s protocol. After isolation, purity was checked by FACS before cultured with RPMI 1640 medium sup-
plemented with 10% FBS, sodium pyruvate, non-essential amino acids, glutamine, 10 mM HEPES and 50 μM 
β-mercaptoethanol. To activate TREG at phtsiological level, Dynabeads were added at bead-to-cell ratio of 2:1 and 
2,000 U of recombinant IL-2 was also supplemented.
CD4+CD25− T effector cells. CD4+CD25− cells were obtained during CD4+CD25+TREG cell isolation. TEFF cell 
culture was supplemented with 30U IL-1 and anti-CD3/CD28 Dynabeads at bead-to-cell ratio of 1:1 for activa-
tion and expansion.
Spleen and lymph nodes. To isolate single cells from the spleen or inguinal lymph nodes, tissues were carefully 
dissected, placed in ice-cold FACS buffer, grinded using the back end of a 3-ml syringe before passing through a 
sterile 70 micro filter. After red blood cell lysis, mononucleated cells were then subjected to either FACS analysis, 
MACS isolation for CD4+ T cells or TREGS, or luciferase activity assay.
BMM-TREG co-culture and transwell culture for osteoclastogenesis assay. BMMs were prepared as aforemen-
tioned. In vitro expanded TREG cells were generated by culturing MACS-isolated splenic naïve CD4+ T cells in 
TREG cell differentiation media (R&D Systems), either with or without the presence of PMMA particles for 2 days 
before directly added onto BMMs for co-culture or into transwell inserts on top of BMMs for transwell culture at 
BMM-TREG ratio of 5:1 or 10:1.
Luciferase assay. Luciferase assay was conducted according to the manufacturer’s protocol (Promega). Briefly, 
freshly isolated or MACS purified cells were lysed in passive cell lysis buffer After protein concentration was 
determined by BCA assay, 20 μg of protein was used from each lysate with Luciferase Assay Reagent to measure 
the light produced by a luminometer.
Nrp-1 knockdown. The lentiviral sgRNA vectors and sequences for targeting Nrp-1 were designed by the 
Genome Center at Washington University. The lentiviral sgRNA bearing a scrambled, non-specific sequence 
was used as control. To generate lentiviral particles, each vector was co-transfected into HEK cells together with 
packaging and helper vectors, replenished with fresh media on the next day. Conditioned media containing lenti-
viral particles was collected after 2 days, concentrated, and stored at −80 upon use. To transduce T cells, 3 million 
spleen derived mouse naive CD4+ T cells were incubated with 300 ul concentrated lentiviral stock in the presence 
of 10 ug/ml polybrene overnight, washed and replenished with TREG cell differentiation media, in the presence or 
absence of PMMA particles for 2 days before proceeding to co-culture experiment with BMMs.
Nrp-1 expression (Gain of function). To achieve expression of Nrp-1 in Tregs, retroviral vector (namely 
PINCO) carrying mouse wildtype Nrp-1 gene was purchased from Addgene (https://www.addgene.org/browse/
gene/18186/). To generate retroviral particles, 5 ug of each PINCO vector plasmid was transfected into 4 millions 
of PLAT-E cells plated on p100 TC dish 1 day prior. After 8 hours, transfected PLAT-E cells were replenished with 
RPMI media supplemented with 10% FBS and 50 uM b-ME. Supernatants were then collected after 48 hours of 
culture and served as retroviral stocks, which were kept on ice until use. To transduce TREGS, 1 millions of freshly 
MACS-isolated naïve CD4+ T cells from mouse spleen were incubated overnight with 3 ml of retroviral stock 
supplemented with reagents from the TREG Cell Differentiation Kit (R&D Systems) and 10ug/ml of polybrene. 
Transduced naïve CD4+ T cells were then washed and replenished with TREG differentiation media and cultured 
for 2 additional days before subjected to co-culture with osteoclast progenitors for in vitro osteoclastogenesis 
assay. To condition PINCO-Nrp1 transduced TREGS, 0.1 mg/ml PMMA particles were added to culture.
Gene expression analysis by RT-qPCR. Cells isolated by MACS or harvested freshly from cultures were lysed in 
Trizol reagent. Total RNAs were isolated and cDNA synthesis was performed according to the manufacturers’ 
protocol. 20 μl of each cDNA sample was diluted by 10-fold with Tris-EDTA buffer and 4 μl of diluted cDNA sam-
ple was used for 10 μl qPCR reaction with SYBR Green PCR mix. Primers for assessing cytokine expressions (IL-
10, IL-17A, M-CSF, RANKL and TNFα) were described previously (Chen et al. 2015). Other primer sequences 
are listed as follows – For CTLA4, forward primer 5′-GCTTCCTAGATTACCCCTTCTGC-3′, reverse primer 
5′-CGGGCATGGTTCTGGATCA-3′; for Dbc1, forward primer 5′-GTATCTCAGTGCAGCCCTCC-3′, reverse 
primer 5′-AACGGGCAAACTCCCTGTAT-3′; for Eos, forward primer 5′-TCTGGACCACGTCATGTTCAC-3′, 
reverse primer 5′-ACGATGTGGGAAGAGAACTCATA-3′; for Foxp3, forward primer 5′-ATTGAGGGTGGGT 
GTCAGGA-3′, reverse primer 5′-ACAGCATGGGTCTGTCTTCTC-3′; for GATA3, forward primer 5′-CCATT 
ACCACCTATCCGCCC-3′, reverse primer 5′-TTCACACACTCCCTGCCTTC-3′, for GITR, forward primer 
5′-CCACTGCCCACTGAGCAATAC, reverse primer 5′-GTAAAACTGCGGTAAGTGAGGG-3′; for Helios, 
forward primer 5′-GAGCCGTGAGGATGAGATCAG-3′; reverse primer 5′-CTCCCTCGCCTTGAAGGTC-3′; 
for Icos, forward primer 5′-ATGAAGCCGTACTTCTGCCG-3′, reverse primer 5′-CGCATTTTTAACTGCT 
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GGACAG-3′; for Nrp-1, forward primer 5′-GACAAATGTGGCGGGACCATA-3′, reverse primer 5′-TGGATTAG 
CCATTCACACTTCTC-3′; for RUNX1, forward primer 5′-CAGGCAGGACGAATCACACT-3′, reverse primer 
5′- CTCGTGCTGGCATCTCTCAT-3′; for RORγT, forward primer 5′-TACCCTACTGAGGAGGACAGG, 
reverse primer 5′-AATGGGGCAGTTCTGCTGAC-3′; for Tbet, forward primer 5′-GTCTGGGAAGCTGAGA 
GTCG-3′, reverse primer 5′-ACATTCGCCGTCCTTGCTTA-3′, for Tpl2, forward primer 5′-ATGGAGTACAT 
GAGCACTGGA-3′, reverse primer 5′-GGCTCTTCACTTGCATAAAGGTT-3′; for Ubc 13, forward primer 
5′-ACAAGAGCAGAGGCCGAAC′3′, reverse primer 5′-GCAAACGCTGGGTTTCCTTG-3′.
Immunohistochemistry. At the end of experiments, mouse long bones were harvested and fixed in 10% neutral 
buffered formalin for 24 hours followed by decalcification in Immunocal (StatLab, McKinney, TX) for 3 days. 
Tissues were then processed, embedded into paraffin, and sectioned 5 mm thick. For immunohistochemistry, 
sections were de-paraffinized and rehydrated using xylene followed by ethanol gradient. Antigen retrieval was 
performed by incubating samples at 60 degrees celsius in Citrate buffer (pH 6.0) followed by quenching of endog-
enous peroxidase activity with 3% H2O2. Sections were blocked using DAKO solution with background reduc-
ing components. Sections were incubated overnight with a 1:200 dilution of anti-Luciferase (Novus), anti-Nrp1 
(Novus) or anti-FoxP3 (Novus) antibody. Sections were rinsed in phosphate-buffered saline (PBS) followed by 
a 1:1000 dilution of biotinylated secondary antibody for one hour. Post-secondary antibody incubation, the sec-
tions were incubated with stereptavidin-HRP (2 ug/ml) for 20 min. After extensive washing with PBS, sections 
were developed using Impact DAB kit (Vector Biolabs).
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